High Yield Advancements Enables Therapeutic Solutions through Mammalian Cell Cultures
Superior cell lines and large-scale manufacturing capabilities will help hinder competition from plant-based expression systems, finds Frost & Sullivan
MOUNTAIN VIEW, Calif., Oct. 22, 2015 /PRNewswire/ -- As healthcare needs increase, the demand for less expensive and effective solutions is rising, pushing novel production hosts such as mammalian expression systems to advance. Mammalian cell culture technologies are a dominant production system, enabling the development of high value biopharmaceutical products. As a result, mammalian expression systems are playing a significant role in the manufacturing of therapeutic proteins, vaccines as well as biosimilars, biosuperiors and biobetters.
Logo - http://photos.prnewswire.com/prnh/20151020/278725LOGO
Analysis from Frost & Sullivan, Trends in Mammalian Cell Cultures (http://bit.ly/1W3sPuS), finds Chinese Hamster Ovary (CHO) cell lines will dominate the industry for the next five years, although efforts to modify CHO cell lines for higher yield will continue. Meanwhile, the soaring costs of sophisticated cell line platforms will pave the way for the use of disposable bags as well as single-use technologies for media and process development.
For complimentary access to more information on this research, please visit: http://bit.ly/1IIA3Jd.
"The benefits of mammalian expression systems are manifold and include improved protein folding as well as modification capabilities at the post-translation and product assembly stages," said TechVision Senior Research Analyst Madhumitha Rangesa. "The emergence of designer mammalian cell lines will further boost, yield and accelerate therapeutic production."
However, adoption will remain slow as the costs of converting processes for work on new cell lines are steep. Another challenge is the complexity in handling mammalian cell lines, with bioreactors and fermentation processes taking close to three weeks in certain cases. Nevertheless, the initiation of disposable bioreactors and designer cell lines will lighten these shortcomings.
"To discourage competition from plant-based expression systems, industry participants must build superior cell lines and new technology platforms with large-scale manufacturing capabilities," suggested Rangesa. "Recognizing this, biopharmaceutical companies are outsourcing production processes to devote greater resources to innovation."
Creating solutions capable of catering to the multi-dimensionality of the industry will revitalize product lines and push mammalian cell culture to a dominant position in biopharmaceutical invention.
Trends in Mammalian Cell Cultures, a part of the TechVision (http://ww2.frost.com/research/technology/health-wellness) subscription, brings out the emerging trends in mammalian cell culture systems on a global scale through a detailed description of technology capability, value chain, drivers, restraints, challenges and technology trends evaluated following extensive interviews with market participants. The study offers an assessment of technology adoption and development by region, demand side analysis, recommendations for technology/product/services developers, and technology management strategies. Further, it provides an evaluation of scenario modeling and emerging opportunities as well as technology management strategies and a technology application roadmap. The research also covers key patents from global participants and offers a detailed list of important contacts in the field.
TechVision is an international technology analysis business that produces a variety of technical news alerts, newsletters, and research services.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
- The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
- The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Trends in Mammalian Cell Cultures
D678
Contact:
Kayla Belcher
Corporate Communications – North America
P: 210.247.2450
F: 210.348.1003
E: [email protected]
http://www.frost.com
http://www.frost.com/techvision
SOURCE Frost & Sullivan
Share this article